Get the Stockscreener App
10.13
0.00%
+0.00
After Hours:
10.13
Embecta Corp stock is currently priced at $10.13, with a 24-hour trading volume of 285.62K.
It has seen a +0.00% increased in the last 24 hours and a -22.73% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $10.18 pivot point. If it approaches the $10.03 support level, significant changes may occur.
Previous Close:
$10.13
Open:
$10.16
24h Volume:
285.62K
Market Cap:
$583.27M
Revenue:
$1.12B
Net Income/Loss:
$55.30M
P/E Ratio:
12.51
EPS:
0.81
Net Cash Flow:
$-30.30M
1W Performance:
-6.98%
1M Performance:
-22.73%
6M Performance:
-33.22%
1Y Performance:
-64.98%
1D Range:
$10.00
$10.47
52W Range:
$9.925
$32.00
Embecta Corp Stock (EMBC) Company Profile
Name
Embecta Corp
Sector
Industry
Phone
201-847-6880
Address
300 Kimball Drive, Parsippany
Embecta Corp Stock (EMBC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-20-23 | Initiated | Wolfe Research | Peer Perform |
| Jan-06-23 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Sep-08-22 | Initiated | BTIG Research | Neutral |
| Aug-01-22 | Initiated | Morgan Stanley | Equal-Weight |
| Jun-21-22 | Initiated | BofA Securities | Underperform |
Embecta Corp Stock (EMBC) Latest News
embecta to Participate in Investor Events
GlobeNewswire Inc.
Cencora (COR) Q2 Earnings Top Estimates
Zacks Investment Research
embecta to Report Fiscal Second Quarter 2024 Financial Results
GlobeNewswire Inc.
embecta-sponsored Educational Symposium and Abstracts at ATTD Highlight Role of Insulin Pumps in the Management of Type 2 Diabetes
GlobeNewswire Inc.
Best Value Stocks to Buy for February 12th
Zacks Investment Research
Embecta Corp. (EMBC) Surpasses Q1 Earnings and Revenue Estimates
Zacks Investment Research
Embecta Corp Stock (EMBC) Financials Data
Embecta Corp (EMBC) Revenue 2024
EMBC reported a revenue (TTM) of $1.12 billion for the quarter ending December 31, 2023, a +0.58% rise year-over-year.
Embecta Corp (EMBC) Net Income 2024
EMBC net income (TTM) was $55.30 million for the quarter ending December 31, 2023, a -65.44% decrease year-over-year.
Embecta Corp (EMBC) Cash Flow 2024
EMBC recorded a free cash flow (TTM) of -$30.30 million for the quarter ending December 31, 2023, a -109.79% decrease year-over-year.
Embecta Corp (EMBC) Earnings per Share 2024
EMBC earnings per share (TTM) was $0.95 for the quarter ending December 31, 2023, a -65.58% decline year-over-year.
About Embecta Corp
Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety devices, as well as digital applications to assist people with managing their diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is based in Parsippany, New Jersey. Embecta Corp.(NasdaqGS:EMBC) operates independently of Becton, Dickinson and Company as of April 1, 2022.
0.69%
0.07%
Cap:
|
Volume (24h):